082P Brighton
Winter Meeting December 2008

Miniribozyme targeted down-regulation of TPH1 in mice protects against chronic hypoxia-induced pulmonary arterial hypertension

Ian Morecroft1, Margaret Nilsen1, Kevin White1, Jens-Uwe Peter2, Diego Walther2, Michael Bader2, Margaret MacLean1

1Glasgow University, Glasgow, UK, 2Max Delbrück Center for Molecular Medicine, Berlin, Germany

Tryptophan hydroxylase 1 (TPH1) mediates the generation of 5-HT in the periphery (Walther et al., 2003). Expression of the Tph1 gene is increased in lungs and pulmonary endothelial cells from patients with idiopathic pulmonary arterial hypertension (PAH) (Eddahibi et al., 2006). Hypoxia-induced PAH is ablated in female mice deficient in TPH1 (Tph1-/- mice (Morecroft et al., 2007)). Recently Peter et al (2007) developed a mouse with reduced 5-HT in plasma and whole blood through selective in vivo down-regulation of the Tph1 gene using TPH1-specific miniribozyme technology (tRz186 mice). To investigate if tRz186 mice are protected against hypoxia-induced PAH, we studied the development of PAH after two weeks of hypoxia in tRz186mice and in mice deficient in Tph1 (Tph1-/- mice) for comparison. Male tRz186, Tph1-/- and wild type (WT) mice (FVB/n, 2-3 months, 25-35g) were subjected to 14 days of either hypobaric hypoxia (10% O2) or normoxia. Under isoflurane anaesthesia, mean systemic arterial pressure (mSAP) was obtained via carotid artery cannulation. Right ventricular pressure (sRVP) was obtained by transdiaphragmatic right ventricular cannulation. Systolic right ventricular (RV) / left ventricle+septum (LV+S) ratio was determined as described previously (Morecroft et al., 2007). Statistical comparisons were made by one-way ANOVA with a Tukey’s multiple comparison test. Data are expressed as mean ± s.e.mean. Results are presented in Table 1. Hypoxia induced increases in sRVP and right ventricular hypertrophy in WT mice. Hypoxia-induced increases in sRVP were ablated in tRz and Tph1-/- mice. Under hypoxia, RV/LV+S was elevated in tRz186 and Tph1-/- mice, despite ablation of sRVP. Neither ribozyme-targeted TPH1 disruption or Tph1 knockout had any effect on mean systemic arterial pressure either under chronic hypoxia or normoxia.

Table 1. Effect of 14 days chronic hypoxia on systolic right ventricular pressure (sRVP), right ventricular weight ratios (RV/LV+S) and mean systemic arterial pressure (mSAP) in WT, tRZ186, and Tph1-/- mice
Groups:sRVP (mmHg)RV/LV+S ratiomSAP(mmHg)n
WT normoxic 22.5 ± 0.6 0.288 ± 0.010 99 ± 5 16
TRz186 normoxic 20.9 ± 0.4 0.305 ± 0.030 99 ± 5 7
Tph1-/- normoxic 24.2 ± 1.0 0.276 ± 0.007 100 ± 3 10
WT hypoxic 40.1 ± 2.1*** 0.426 ± 0.020*** 99±5 7
TRz186 hypoxic 25.9 ± 1.7* 0.424 ± 0.030*** 99±5 6
Tph1-/- hypoxic 26.2 ± 0.7 0.347 ± 0.02* 97±4 7

Statistical analysis by ANOVA; *P<0.05,***P <0.001 compared with respective normoxic counterparts; n = number of animals

tRz186 (and Tph1-/-) mice are resistant to chronic hypoxia-induced PAH. TPH1 is essential for the development of hypoxia-induced PAH, whilst having differential effects on right ventricular hypertrophy under hypoxic conditions. TPH1 could be a promising new therapeutic target in treating PAH.

Eddahibi S., et al., (2006). Circulation 113:1857-64;

Morecroft I., et al., (2007). Hypertension 49: 232-236;

Peter J.U, et al., (2006). Moll Cell Biochem. 295:205-215;

Walther D.J., et al., (2003). Biochemical Pharmacology: 66:1673-1680